Literature DB >> 25865435

Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.

Richard G Abramson1, Katrina F Lambert2, Laurie B Jones-Jackson2, Lori R Arlinghaus3, Jason Williams3, Vandana G Abramson4, A Bapsi Chakravarthy5, Thomas E Yankeelov3.   

Abstract

RATIONALE AND
OBJECTIVES: Prone (18)F fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) may have advantages for breast imaging because of improved separation of deep anatomic structures. There are limited data on whether prone and supine FDG-PET/CT provide similar information regarding breast and axillary disease in the setting of locally advanced breast cancer (LABC). The purpose of this study was to compare the information on locoregional disease distribution provided by prone versus supine FDG-PET in newly diagnosed LABC.
MATERIALS AND METHODS: In an Institutional Review Board-approved prospective trial, 24 patients with newly diagnosed LABC underwent both supine and prone FDG-PET/CT at the same scanning session. Three readers performed an independent review of all scans and categorized the locoregional disease distribution as breast only (BO)-unifocal, BO-multifocal, BO-multicentric, or breast + axillary involvement. For breast + axillary disease, the readers also assessed the number of involved axillary lymph nodes. Interobserver discrepancies were resolved at a consensus reading session.
RESULTS: Two scanning sessions were excluded because the prone scan had omitted part of the axilla from the field of view. In the remaining 22 patients, the consensus categorization of anatomic disease distribution was concordant between prone and supine scanning in 21 patients (linear kappa 0.91, 95% confidence interval [0.79-1]). In the 16 patients with breast + axillary disease, equal numbers of involved lymph nodes were identified on prone and supine scanning in 12 patients, whereas in the remaining four patients, prone scanning resulted in a higher number of visualized lymph nodes.
CONCLUSIONS: Prone and supine FDG-PET/CT provided statistically identical information on locoregional disease distribution in LABC. However, prone scanning may perform better than supine for assessing the number of involved lymph nodes. Prone FDG-PET/CT may be useful in future clinical and research efforts, including hybrid PET-magnetic resonance imaging (MRI) applications.
Copyright © 2015 AUR. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neoadjuvant chemotherapy; nodal disease burden; radiation planning; risk stratification

Mesh:

Substances:

Year:  2015        PMID: 25865435      PMCID: PMC4464958          DOI: 10.1016/j.acra.2015.02.012

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  17 in total

1.  Effect of patients' being prone during FDG PET for the diagnosis of breast cancer.

Authors:  K Yutani; M Tatsumi; T Uehara; T Nishimura
Journal:  AJR Am J Roentgenol       Date:  1999-11       Impact factor: 3.959

2.  Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.

Authors:  A Recht; S B Edge; L J Solin; D S Robinson; A Estabrook; R E Fine; G F Fleming; S Formenti; C Hudis; J J Kirshner; D A Krause; R R Kuske; A S Langer; G W Sledge; T J Whelan; D G Pfister
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans.

Authors:  Linda Moy; Marilyn E Noz; Gerald Q Maguire; Fabio Ponzo; Abby E Deans; Antoinette D Murphy-Walcott; Elissa L Kramer
Journal:  Clin Nucl Med       Date:  2007-03       Impact factor: 7.794

4.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  S Aebi; T Davidson; G Gruber; F Cardoso
Journal:  Ann Oncol       Date:  2011-09       Impact factor: 32.976

5.  Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.

Authors:  Eugene H Huang; Susan L Tucker; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Aman U Buzdar; Vicente Valero; George H Perkins; Naomi R Schechter; Kelly K Hunt; Aysegul A Sahin; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

Review 6.  Performance of FDG PET/CT in the clinical management of breast cancer.

Authors:  David Groheux; Marc Espié; Sylvie Giacchetti; Elif Hindié
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

7.  Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.

Authors:  Richard L Wahl; Barry A Siegel; R Edward Coleman; Constantine G Gatsonis
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

8.  Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.

Authors:  Massimo Imbriaco; Maria Grazia Caprio; Gennaro Limite; Leonardo Pace; Teresa De Falco; Ermanno Capuano; Marco Salvatore
Journal:  AJR Am J Roentgenol       Date:  2008-11       Impact factor: 3.959

Review 9.  Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi.

Authors:  I Khalkhali; I Mena; L Diggles
Journal:  Eur J Nucl Med       Date:  1994-04

10.  Defining the role of PET-CT in staging early breast cancer.

Authors:  Ashley M Groves; Manu Shastry; Simona Ben-Haim; Irfan Kayani; Anmol Malhotra; Timothy Davidson; Tina Kelleher; Diane Whittaker; Marie Meagher; Brian Holloway; Ruth M Warren; Peter J Ell; Mohammed R Keshtgar
Journal:  Oncologist       Date:  2012-04-26
View more
  5 in total

Review 1.  Potential Clinical Applications of 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Mammography in Breast Cancer.

Authors:  Ihn-Ho Cho; Eun-Jung Kong
Journal:  Nucl Med Mol Imaging       Date:  2016-08-30

2.  Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.

Authors:  Jason M Williams; Sudheer D Rani; Xia Li; Lori R Arlinghaus; Tzu-Cheng Lee; Lawrence R MacDonald; Savannah C Partridge; Hakmook Kang; Jennifer G Whisenant; Richard G Abramson; Hannah M Linden; Paul E Kinahan; Thomas E Yankeelov
Journal:  Med Phys       Date:  2015-07       Impact factor: 4.071

3.  Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer.

Authors:  Angela M Jarrett; David A Hormuth; Vikram Adhikarla; Prativa Sahoo; Daniel Abler; Lusine Tumyan; Daniel Schmolze; Joanne Mortimer; Russell C Rockne; Thomas E Yankeelov
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

4.  Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer.

Authors:  Jennifer G Whisenant; Jason M Williams; Hakmook Kang; Lori R Arlinghaus; Richard G Abramson; Vandana G Abramson; Kareem Fakhoury; A Bapsi Chakravarthy; Thomas E Yankeelov
Journal:  Tomography       Date:  2020-06

5.  Investigation of Added Value of Imaging Performed in a Prone Position to Standard 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Staging in Patients with Breast Cancer.

Authors:  Ezgi Başak Erdoğan; Mehmet Aydın
Journal:  Mol Imaging Radionucl Ther       Date:  2022-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.